Evidence map›Paper›PMID 36705401›Full record

ArticleImmunity, inflammation and disease2023

Effect of MP-AzeFlu compared to monotherapy on COX-2, PGE

Sonia Vicens-Artes, Jordi Roca-Ferrer, Valeria Tubita, Mireya Fuentes, Isam Alobid, Antonio Valero, Ferdinand Kopietz, DucTung Nguyen, Joaquim Mullol

Open access · goldAbstract read
In one paragraph

Article in Immunity, inflammation and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Trial
  2. Effect of MP-AzeFlu compared to monotherapy on COX-2, PGEImmunity, inflammation and disease · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sonia Vicens-ArtesClinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.ORCID 0000-0002-3839-0417
Jordi Roca-FerrerClinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.
Valeria TubitaClinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.
Mireya FuentesClinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.
Isam AlobidClinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.
Antonio ValeroClinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.
Ferdinand KopietzMEDA Pharma GmbH & Co. KG (A Viatris Company), Bad Homburg, Germany.
DucTung NguyenMEDA Pharma GmbH & Co. KG (A Viatris Company), Bad Homburg, Germany.
Joaquim MullolClinical and Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MP-AzeFlu (intranasal fluticasone and azelastine) has been widely studied and has demonstrated efficacy in Allergic rhinitis with a superior effect compared to these drugs administered individually; however, the mechanism by which MP-AzeFlu produces this improved clinical effect has not yet been fully explained. In this study, we investigated the effect of MP-AzeFlu and fluticasone propionate (FP) on arachidonic acid metabolism as measured by changes in regulation of cyclooxygenase (COX) isoforms, prostaglandin (PG) D

Indexed as

DinoprostoneMucous MembraneCyclooxygenase 2FluticasoneHumansInflammationRNA, MessengerCyclooxygenase 2DinoprostoneFluticasoneRNA, MessengerCOX-2EP2fluticasoneMP-AzeFluPGE2

Identifiers

PMID36705401
PMCPMC9753815
OpenAlexW4311782363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.